In clinical studies, Mirataz® achieved measurable and steady plasma levels of mirtazapine and effectively resulted in weight gain
MIRTAZAPINE CONCENTRATIONS IN CATS AT STEADY STATE FOLLOWING DAILY DOSING
(DAY 13; 0.5 MG/KG)1
Mirataz demonstrated a 3.9% increase in body weight in cats with unintended weight loss in as little as 14 days2
WEIGHT GAIN IN CATS WITH MIRATAZ VS PLACEBO
(EFFECTIVENESS POPULATION)
STUDY DESIGN: Randomized, double-blind, placebo-controlled study (N=177)
Mirataz was effective in the management of weight loss in cats associated with a wide variety of conditions2
Mirataz is indicated for the management of weight loss in cats.
Important Safety Information
Mirataz® (mirtazapine transdermal ointment) is for topical use in cats only under veterinary supervision. Do not use in cats with a known hypersensitivity to mirtazapine or any of the excipients. Do not use in cats treated with monoamine oxidase inhibitors (MAOIs). Not for human use. Keep out of reach of children. Wear gloves when handling/applying, wash hands after and avoid contact between the treated cat and people or other animals for 2 hours following application. Use with caution in cats with hepatic and kidney disease. Cat’s food intake should be monitored upon discontinuation. Safety has not been evaluated in cats less than 2 kg, less than six months of age or in breeding, pregnant or lactating cats. The most common adverse reactions observed during clinical trials were application site reactions, behavioral abnormalities (vocalization and hyperactivity) and vomiting. For product label, including complete safety information, click here.
References
1. Buhles W, Quimby JM, Labelle D, et al. Single and multiple dose pharmacokinetics of a novel transdermal ointment in cats. J Vet Pharmacol Therap. 2018;41(5):644-651.
2. Poole M, Quimby JM, Hu T, et al. A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss. J Vet Pharmacol Ther. 2019;42(2):179-188.
US Patent 10,603,272
Mirataz® is a registered trademark of Dechra Ltd.